Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026 to review fourth quarter and full year 2025 financial results and provide business updates.
Investors can access the event via the company’s Investor Events page; an archived webcast will be posted on the Wave Life Sciences website after the live event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, WVE gained 0.95%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
WVE gained 3.97% while close peers were mixed: CVAC +1.97%, ELVN +1.46%, STOK +0.45%, PGEN -5.79%, ZYME -0.26%, indicating stock-specific factors rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-11-10 | Q3 2025 earnings | Neutral | -10.3% | Reported Q3 2025 financials with detailed WVE-007 and WVE-006 data. |
| 2025-11-04 | Earnings call scheduled | Neutral | -3.6% | Announced November 10, 2025 Q3 results webcast and conference call. |
| 2025-07-30 | Q2 2025 earnings | Neutral | -1.9% | Released Q2 2025 results and pipeline progress for key programs. |
| 2025-07-23 | Earnings call scheduled | Neutral | +7.9% | Set July 30, 2025 webcast to discuss Q2 2025 results. |
| 2025-05-08 | Q1 2025 earnings | Neutral | +0.8% | Reported Q1 2025 results and multiple clinical pipeline updates. |
Earnings-tagged events over the past year showed an average move of -1.43%, suggesting a modestly negative historical bias around financial updates.
Across 2025, Wave Life Sciences delivered a steady cadence of quarterly financial updates paired with clinical progress. Q1–Q3 2025 earnings releases highlighted advancing programs such as WVE-006 for AATD, WVE-007 for obesity, and WVE-N531 and WVE-003 in neuromuscular and CNS indications. Two scheduling releases set expectations for Q2 and Q3 calls. Historically, share reactions to these earnings-related communications have been mixed, with several negative sessions and a few positive days around updates.
Historical Comparison
Earnings-related announcements for WVE over the past year averaged a -1.43% move, with a mix of result reports and call-scheduling releases similar to this Q4/full-year 2025 notice.
Earnings communications in 2025 progressed from Q1 through Q3 results, with scheduled calls for Q2 and Q3. The new announcement continues this pattern by setting expectations for the upcoming Q4 and full-year 2025 financial disclosure.
Market Pulse Summary
This announcement schedules Wave’s Q4 and full-year 2025 earnings call for February 26, 2026 at 8:30 a.m. ET, continuing a consistent cadence of quarterly updates seen throughout 2025. Historical earnings-related releases have produced mixed share reactions, with an average move of -1.43%. Investors may focus on upcoming disclosures about cash runway, recent capital raises, and progress across key RNA programs when the full results are released.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
FAQ
When will Wave Life Sciences (WVE) present its Q4 and full year 2025 results?
How can investors access the Wave Life Sciences (WVE) February 26, 2026 webcast?
Will the Wave Life Sciences (WVE) February 26, 2026 webcast be available after the live event?
Can analysts ask questions during the Wave Life Sciences (WVE) February 26, 2026 call?
Where is the Wave Life Sciences (WVE) investor event information posted for the February 26, 2026 presentation?
